Clinical trial · Observational
AnovaOS Network Powered Patient Registry
NCT05013944CI-TRIAL-00073425unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objective of this study is the development, implementation and management of a registry of patient data that captures clinically meaningful, real-world, data on the diagnosis, nature, course of infection, treatment(s) and outcomes in patients with complex disease globally.
Conditions
Conditions (21)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Certain Conditions Originating in the Perinatal Period | — | UNRESOLVED | — |
| Congenital Malformations, Deformations and Chromosomal Abnormalities (Q00-Q99) | — | UNRESOLVED | — |
| Diseases of the Blood and Blood-Forming Organs and Certain Disorders Involving the Immune Mechanism (D50-D89) | — | UNRESOLVED | — |
| Diseases of the Circulatory System | — | UNRESOLVED | — |
| Diseases of the Digestive System | — | UNRESOLVED | — |
| Diseases of the Ear and Mastoid Process | — | UNRESOLVED | — |
| Diseases of the Eye and Adnexa | — | UNRESOLVED | — |
| Diseases of the Genitourinary System | — | UNRESOLVED | — |
| Diseases of the Musculoskeletal System and Connective Tissue | — | UNRESOLVED | — |
| Diseases of the Nervous System | — | UNRESOLVED |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (4)
- measure
- Assess Natural history
- timeFrame
- 5 years
- description
- Assessing natural history, including estimating the magnitude of a problem; determining the underlying incidence or prevalence rate of a condition; examining trends of disease over time; assessing service delivery and identifying groups at high risk; and describing and estimating survival;
- measure
- Assess Clinical, Cost and/or Comparative Effectiveness
- timeFrame
- 5 years
- description
- Determining clinical effectiveness, cost effectiveness, or comparative effectiveness of a test or a treatment;
- measure
- Assess Safety
- timeFrame
- 5 years
- description
- Measuring and monitoring safety and harm associated with the use of specific products and treatments, including conducting comparative evaluation of safety and effectiveness;
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 18 years old or older; * Confirmed positive diagnosis of disease, condition or disorder. This will be self-reported or reported by the patient's provider, advocacy group or other patient representative; * Laboratory or other independent means of confirmation is not required but may be confirmed in clinical trials; * Able to understand and willing to sign the informed consent document; or whose legal representative has given consent to participate in the research per state and Federal requirements; * Willing and able to complete the registry questions or have the instrument(s) completed by an informed proxy; * Anticipated additional follow up with the registry once per year. Exclusion Criteria: * Subjects who do not meet the inclusion criteria for the study; * Subjects who are unable to understand the protocol or unable to provide legally effective informed consent
References
Publications (0)
Data not yet available
No reference posted for this study.